Daniel M. Bradbury
Managing Member, BioBrit, LLC
Dan Bradbury is a Life Sciences Executive with over 30 years of experience creating and implementing strategies that transform businesses, bring novel medicines to market and maximize shareholder value. He is the Managing Member of BioBrit, LLC, a Life Sciences Consulting and Investment Firm. Dan is the former President, Chief Executive Officer and Director of Amylin Pharmaceuticals, a biopharmaceutical company based in San Diego, CA, focused on metabolic diseases. During his 18-year tenure at Amylin, the company launched three first-in-class medicines, including the first once-a-week therapy to treat diabetes and was listed on the Nasdaq 100. He served as Amylin’s Chief Executive Officer from March 2007 until its acquisition by Bristol-Myers Squibb Company for $7 billion in August 2012. Before joining Amylin, Dan worked in marketing and sales roles for ten years at SmithKline Beecham Pharmaceuticals. He serves on the board of directors of Biocon Limited, Corcept Therapeutics, Geron Corporation, Illumina, Inc., Castle Biosciences, Inc., DiaVacs, Inc., Freedom Meditech, Inc., Liquid Grids, Inc., Microdermis, Inc., Profil Institute for Clinical Research, Inc., Renova Therapeutics, Sensulin, Inc. and Troia Therapeutics, Inc. He also serves on the board of the Riecken Community Libraries, the board of trustees of the Keck Graduate Institute, the Investor Growth Capital Advisory Board, the BioMed Ventures Advisory Committee, the University of California San Diego’s Rady School of Management's Advisory Council and the board of ADCY5.org. Dan received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom.
Mette Kristine Agger
Managing Partner, Lundbeckfonden Ventures
Mette Kirstine has a broad international experience within biotech / life science covering business development and licensing, management and financing. She was previously co-founder and CEO of 7TM Pharma A/S and prior to this, Mette was part of the management team of NeuroSearch A/S responsible for business development and licensing. She started her carrier as Patent Agent and has over the years co-founded several biotech companies. Mette has been appointed to numerous board positions both in private and public companies. Mette Kirstine Agger graduated as Biologist from the University of Copenhagen and has an MBA.
Operating Partner, Frazier Healthcare
Dr. Chaudhuri has more than 25 years of experience in pharmaceuticals management, drug research & development, and commercialization in the US, EU and emerging markets. He has led the development and FDA approval of multiple NDAs and ANDAs. Most recently, Dr. Chaudhuri served as President of Valeant Pharmaceuticals before becoming an Operating Partner at Frazier Healthcare. Prior to joining Valeant, Dr. Chaudhuri served as President and CEO of Dow Pharmaceuticals leading up to their acquisition by Valeant. Before Dow, Dr. Chaudhuri worked at Bertek Pharmaceuticals (a subsidiary of Mylan Laboratories) as Executive Vice President of Scientific Affairs and as the General Manager of the Dermatology Division of Mylan Laboratories. Dr. Chaudhuri holds a Doctorate in Physical Pharmacy.
Venture Partner, Novartis Ventures, Cambridge
Giovanni Ferrara joined Novartis Venture Funds in 2011. Prior, he spent three years as a consultant to leading west coast venture capital firms and portfolio companies. Most recently, he was consulting Chief Business Officer to Sorbent Therapeutics, where he raised $58M in two financings and led a refocusing of the company’s clinical activities and business development strategy. Previously, he was Managing Director and General Partner at Burrill& Company, and began his venture capital career at GeneChem Management, where he invested and also held operating positions in portfolio companies, including CEO of Targanta Therapeutics (then PhageTech, Inc.). He began his career in healthcare as a pharmacist at a cancer treatment center researching experimental therapies. He received his MBA and MSc at McGill University.
Gordon Foulkes, PhD
Chief Executive Officer, Thesan Pharmaceuticals, Inc.
Dr. Foulkes has over 25 years of experience in biopharmaceutical Executive Management R&D and Venture Capital. From 2007-2009, he served as the founding CEO of Excaliard Pharmaceuticals, and resumed that role in 2010, to lead the acquisition of Excaliard by Pfizer in 2011. Dr. Foulkes also served as a Managing Director of RiverVest Ventures from 2005-2010. Previously, he headed R&D, and served on the Boards of multiple biotechnology companies, including Redwood Biosciences (as Exec. Chairman, acquired by Catalent in 2014), Oncogene Science, Inc. (NASDAQ: OSIP; acquired by Astellas for $4 billion in 2010), Aurora Biosciences (NASDAQ: ABSC; acquired by Vertex for $590M in 2001), and Elitra Pharmaceuticals (acquired by Merck). Dr. Foulkes has had a lead role in securing more than 15 corporate partnerships, resulting in over $350 million in recognized revenues, as well as directly participated in raising over $245 million in private, IPO and follow-on public offerings. Prior to joining Industry, he held academic positions at both MIT and the Medical Research Council (UK).
Managing Partner, SV Life Sciences
Dr. Michael Ross joined SVLS as a Venture Partner in 2001, became a Managing Partner in 2002 and is based in San Francisco. Michael serves on the Thayer School of Engineering (Dartmouth College). He has also served on the boards of Carta Proteomics, Epimmune, Genencor, MetaXen, and Xenova. Michael was the tenth employee at Genentech where he worked for 13 years. He served as Genentech team leader for Humulin® (human insulin-Lilly), Roferon® (Interferon alpha -Roche), Protropin® (hGH), Vice President of Development during the development of Activase®, Nutropin® and Pulmozyme®. Michael then started Genentech's protein engineering and small molecule discovery effort as Vice President of Medicinal and Biomolecular Chemistry. Michael was the Founding CEO of Arris Pharmaceutical, MetaXen, ExSAR and CyThera (now Novocell). Michael was also Managing Partner in Didyma, LLC, a biotechnology management consulting firm.Michael received his AB from Dartmouth College, his PhD in Chemistry at Caltech, and completed a Post Doctorate in Molecular Biology at Harvard.